A new strain of the coronavirus recently surfaced in Southern California, concerning public health officials as it spreads worldwide. Los Angeles Times executive chairman Dr. Patrick Soon-Shiong answers four key questions about the California variant.
Patrick Soon-Shiong is a surgeon and scientist who has spent his career studying the human immune system to fight cancer and infectious disease. Last year, Soon-Shiong's company, ImmunityBio, received permission from the Food and Drug Administration to begin Phase 1 trials of its COVID-19 vaccine candidate. He has also received approval to begin trials in South Africa, where he will explore the potential of his T cell vaccine to prevent infection from mutated virus strains of the coronavirus.
SUBSCRIBE FOR MORE VIDEOS AND NEWS
http://www.youtube.com/subscription_center?add_user=losangelestimes
https://www.latimes.com/subscription
LET’S CONNECT:
Facebook ► https://www.facebook.com/latimes
Twitter ► https://twitter.com/LATimes
Instagram ► https://www.instagram.com/latimes
Patrick Soon-Shiong is a surgeon and scientist who has spent his career studying the human immune system to fight cancer and infectious disease. Last year, Soon-Shiong's company, ImmunityBio, received permission from the Food and Drug Administration to begin Phase 1 trials of its COVID-19 vaccine candidate. He has also received approval to begin trials in South Africa, where he will explore the potential of his T cell vaccine to prevent infection from mutated virus strains of the coronavirus.
SUBSCRIBE FOR MORE VIDEOS AND NEWS
http://www.youtube.com/subscription_center?add_user=losangelestimes
https://www.latimes.com/subscription
LET’S CONNECT:
Facebook ► https://www.facebook.com/latimes
Twitter ► https://twitter.com/LATimes
Instagram ► https://www.instagram.com/latimes
- Category
- U.S. & Canada
- Tags
- Los Angeles Times, LA Times, L. A. Times
Sign in or sign up to post comments.
Be the first to comment